Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dauh-Rurng Wu

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Journal of Medicinal Chemistry|December 2, 2020
Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design ApproachesHai-Yun Xiao, Ning Li, James J-W Duan, et al.
Journal of Medicinal Chemistry|August 31, 2022
The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 MaturationAlicia Regueiro-Ren, Sing-Yuen Sit, Yan Chen, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical TrialsT G Murali Dhar, Hai-Yun Xiao, Jenny Xie, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse AgonistRobert J Cherney, Lyndon A M Cornelius, Anurag Srivastava, et al.
Bioorganic & Medicinal Chemistry Letters|December 14, 2017
Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivityHua Gong, David S Weinstein, Zhonghui Lu, et al.
Journal of Medicinal Chemistry|December 23, 2016
Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P<sub>1</sub> Receptor ModulatorMichael G Yang, Zili Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic TherapyAndrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and PsoriasisQingjie Liu, Hai-Yun Xiao, Douglas G Batt, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2014
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agentYoon T Jeon, Wu Yang, Jennifer X Qiao, et al.
Journal of Medicinal Chemistry|May 24, 2025
Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor ActivitySayumi Yamazoe, Yam Poudel, Emanuela Sega, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Journal of Medicinal Chemistry|December 2, 2020
Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design ApproachesHai-Yun Xiao, Ning Li, James J-W Duan, et al.
Journal of Medicinal Chemistry|August 31, 2022
The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 MaturationAlicia Regueiro-Ren, Sing-Yuen Sit, Yan Chen, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical TrialsT G Murali Dhar, Hai-Yun Xiao, Jenny Xie, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse AgonistRobert J Cherney, Lyndon A M Cornelius, Anurag Srivastava, et al.
Bioorganic & Medicinal Chemistry Letters|December 14, 2017
Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivityHua Gong, David S Weinstein, Zhonghui Lu, et al.
Journal of Medicinal Chemistry|December 23, 2016
Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P<sub>1</sub> Receptor ModulatorMichael G Yang, Zili Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic TherapyAndrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Azatricyclic Inverse Agonists of RORγt That Demonstrate Efficacy in Models of Rheumatoid Arthritis and PsoriasisQingjie Liu, Hai-Yun Xiao, Douglas G Batt, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2014
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agentYoon T Jeon, Wu Yang, Jennifer X Qiao, et al.
Journal of Medicinal Chemistry|May 24, 2025
Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor ActivitySayumi Yamazoe, Yam Poudel, Emanuela Sega, et al.
Pageof 7